To evaluate efficacy and safety of subcutaneous ( SC ) and intravenous ( IV ) abatacept and background methotrexate ( MTX ) in Japanese patients with rheumatoid arthritis ( RA ) and inadequate response to MTX ( MTX-IR ) .